Technical Analysis for ACXP - Acurx Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Expansion Breakdown | Bearish Swing Setup | 0.00% | |
| Reversal New Lows Setup | Bearish Swing Setup | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Wide Range Bar | Range Expansion | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| BB Squeeze Ended | Range Expansion | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 21 hours ago |
| Down 5% | about 22 hours ago |
| New 52 Week Low | about 22 hours ago |
| Down 10% | about 22 hours ago |
| Down 2 ATRs | about 22 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/12/2024
Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Care Antibiotics Bacterial Infections Staphylococcus Aureus Methicillin Gram Positive Bacteria Vancomycin
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Care Antibiotics Bacterial Infections Staphylococcus Aureus Methicillin Gram Positive Bacteria Vancomycin
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.28 |
| 52 Week Low | 1.18 |
| Average Volume | 61,668 |
| 200-Day Moving Average | 2.22 |
| 50-Day Moving Average | 1.93 |
| 20-Day Moving Average | 1.81 |
| 10-Day Moving Average | 1.75 |
| Average True Range | 0.12 |
| RSI (14) | 14.53 |
| ADX | 29.4 |
| +DI | 5.33 |
| -DI | 46.07 |
| Chandelier Exit (Long, 3 ATRs) | 1.61 |
| Chandelier Exit (Short, 3 ATRs) | 1.53 |
| Upper Bollinger Bands | 2.05 |
| Lower Bollinger Band | 1.58 |
| Percent B (%b) | -0.4 |
| BandWidth | 25.96 |
| MACD Line | -0.09 |
| MACD Signal Line | -0.06 |
| MACD Histogram | -0.0338 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.22 | ||||
| Resistance 3 (R3) | 2.24 | 1.98 | 2.08 | ||
| Resistance 2 (R2) | 1.98 | 1.77 | 1.97 | 2.03 | |
| Resistance 1 (R1) | 1.69 | 1.64 | 1.56 | 1.67 | 1.99 |
| Pivot Point | 1.43 | 1.43 | 1.37 | 1.42 | 1.43 |
| Support 1 (S1) | 1.14 | 1.22 | 1.01 | 1.12 | 0.79 |
| Support 2 (S2) | 0.88 | 1.09 | 0.87 | 0.75 | |
| Support 3 (S3) | 0.59 | 0.88 | 0.70 | ||
| Support 4 (S4) | 0.57 |
